Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $249.83 | 8 | 51.6% |
| Education | $233.95 | 4 | 48.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $99.95 | 1 | $0 (2021) |
| Seagen Inc. | $99.00 | 1 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $74.93 | 1 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $73.74 | 3 | $0 (2024) |
| Pharmacyclics LLC, an AbbVie Company | $47.82 | 1 | $0 (2022) |
| Aveo Pharmaceuticals, Inc. | $35.00 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $29.34 | 2 | $0 (2022) |
| TG Therapeutics, Inc. | $24.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $153.33 | 5 | Regeneron Healthcare Solutions, Inc. ($74.93) |
| 2023 | $30.34 | 1 | Janssen Scientific Affairs, LLC ($30.34) |
| 2022 | $101.16 | 4 | Pharmacyclics LLC, an AbbVie Company ($47.82) |
| 2021 | $198.95 | 2 | Amgen Inc. ($99.95) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: Oncology | ||||||
| 03/26/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 01/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $74.93 | General |
| Category: ONCOLOGY | ||||||
| 09/01/2023 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $30.34 | General |
| Category: Oncology | ||||||
| 10/06/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: ONCOLOGY | ||||||
| 05/19/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $47.82 | General |
| Category: ONCOLOGY | ||||||
| 03/24/2022 | TG Therapeutics, Inc. | UKONIQ (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Hematology | ||||||
| 06/02/2021 | Seagen Inc. | — | Education | In-kind items and services | $99.00 | General |
| 04/19/2021 | Amgen Inc. | — | Education | In-kind items and services | $99.95 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 530 | 896 | $418,523 | $85,378 |
| 2022 | 44 | 2,231 | 29,273 | $1.1M | $310,187 |
| 2021 | 25 | 992 | 1,813 | $242,383 | $69,732 |
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 96 | 289 | $144,275 | $31,419 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 147 | 262 | $92,748 | $19,367 | 20.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 72 | 72 | $51,192 | $9,873 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 61 | $30,531 | $6,471 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 68 | $24,072 | $5,115 | 21.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 42 | 42 | $23,856 | $3,540 | 14.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 22 | $15,378 | $2,977 | 19.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $15,642 | $2,525 | 16.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $10,224 | $1,665 | 16.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 25 | $6,225 | $1,543 | 24.8% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2023 | 14 | 15 | $4,380 | $883.95 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 273 | 714 | $250,614 | $65,149 | 26.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 12 | 3,120 | $173,700 | $53,792 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 123 | 318 | $149,460 | $43,460 | 29.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 40 | 320 | $142,903 | $42,449 | 29.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 46 | 171 | $76,950 | $17,678 | 23.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 15 | 17,250 | $51,750 | $15,386 | 29.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 253 | 809 | $21,843 | $8,382 | 38.4% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2022 | 15 | 1,250 | $32,410 | $8,111 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $31,968 | $7,883 | 24.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 264 | 836 | $16,720 | $6,374 | 38.1% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2022 | 77 | 253 | $11,638 | $4,534 | 39.0% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 45 | 171 | $17,100 | $4,167 | 24.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 31 | 120 | $12,000 | $2,777 | 23.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 16 | 53 | $11,554 | $2,701 | 23.4% |
About Dr. Bryden Considine, DO
Dr. Bryden Considine, DO is a Hematology & Oncology healthcare provider based in Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2014. The National Provider Identifier (NPI) number assigned to this provider is 1356760839.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bryden Considine, DO has received a total of $483.78 in payments from pharmaceutical and medical device companies, with $153.33 received in 2024. These payments were reported across 12 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($249.83).
As a Medicare-enrolled provider, Considine has provided services to 3,753 Medicare beneficiaries, totaling 31,982 services with total Medicare billing of $465,296. Data is available for 3 years (2021–2023), covering 80 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Bend, OR
- Active Since 04/10/2014
- Last Updated 02/06/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356760839
Products in Payments
- LIBTAYO (Biological) $74.93
- ERLEADA (Drug) $73.74
- IMBRUVICA (Drug) $47.82
- FOTIVDA (Drug) $35.00
- SCEMBLIX (Drug) $29.34
- UKONIQ (Drug) $24.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Bend
Hyung-Chil Kang, M.d, M.D
Hematology & Oncology — Payments: $26,936
Dr. Natasha Tiffany, M.d, M.D
Hematology & Oncology — Payments: $18,544
Pradip Rustagi, Md, MD
Hematology & Oncology — Payments: $13,450
Dr. Andrew Chen, D.o, D.O
Hematology & Oncology — Payments: $11,691
Dr. Christina Fitzmaurice, M.d, M.D
Hematology & Oncology — Payments: $1,141
Dr. Richard Reed, Md, MD
Hematology & Oncology — Payments: $568.67